

MEDIAKIT 2025



INDEX


*Bioconjugation Insights—
your content marketing
partner for life sciences*

ABOUT	3	ARTICLES	17
WHAT CAN WE DO FOR YOU?	5	INTERVIEWS AND PODCASTS	18
USER DEMOGRAPHICS	7	VIDEO PRESENTATIONS	20
CALENDAR	11	INFOGRAPHICS	21
WHO WE WORK WITH	12	SCIENTIFIC ILLUSTRATIONS	22
OPPORTUNITIES	13	EBLASTS	23
WEBINARS	13	PREMIUM SERVICES	24
EXPERT ROUNDTABLES	16	OUR OTHER PUBLICATIONS	25

ABOUT

Bioconjugation Insights—the first and only dedicated digital content channel designed for the bioconjugation community of experts

Bioconjugation Insights provides a unique platform for the bioconjugation community's experts to explore key current trends,



Core areas for coverage include, but are not limited to: ADCs; antibody-oligonucleotide conjugates (AOCs); bispecific ADCs (BsADCs); conjugated vaccines; diagnostic and imaging tools; enzyme conjugates; nanoparticle conjugates; polymer conjugates (including PEGylation); protein and peptide conjugates (PPCs); radioconjugates; targeted drug delivery; and theranostics.

Bioconjugation Insights comprehensive scope and coverage spans engineering and design, manufacturing and supply chain, preclinical and clinical R&D, regulation, financing, market access, and more.

Bioconjugation Insights is the first and only dedicated digital content channel specifically designed to keep industry and academic professionals up to date with this truly global sector's evolution on a genuinely worldwide scale.

Bioconjugation Insights provides a unique online content marketing and lead-generation opportunity

Is it important for your company to demonstrate its capabilities to scientists and/or business leaders making key technology platform decisions at an early stage in a product's development?

Do you need to generate qualified leads from companies involved in bioconjugate manufacturing and R&D?

Are you looking to provide educational materials to individuals focused on analytical, process, or clinical development?

Bioconjugation Insights provides a unique online content marketing and lead-generation opportunity for:

- ▶ active engagement of key stakeholders from across the global community all year round;
- ▶ the chance to target organizations at varying stages of the R&D pipeline—universities, spin-outs, biotechs, pharma, hospitals, investors, and analysts;
- ▶ an alternative to the ever-more expensive conference market; and
- ▶ a means by which you can access the people making the key new discoveries, those individuals driving the delivery of safe and effective bioconjugate therapies to patients, and those designing, developing, and producing the delivery, linker, and payload technologies.

WHAT CAN WE DO FOR YOU?

We don't sell off-the-shelf solutions: all the packages we provide are tailored to your precise marketing, educational and business development objectives

We can:

- ▶ provide support in the development of your content marketing strategy and tactics for this sector, partnering with you in the development of your annual marketing plans;
- ▶ work closely with you to create quality written, video, and audio content of high value to your target audience;
- ▶ offer you opportunities to re-purpose scientific and educational content you have already developed and make it available to a global audience;
- ▶ raise your company's profile, demonstrate your capabilities, and enhance your reputation as a thought-leader in the sector;
- ▶ play a key role in your lead-generation activities;
- ▶ ensure your leading scientists are seen as subject matter experts throughout your target market; and
- ▶ create written content from video or audio, ideal for increasing the reach, longevity, and searchability of your data and other technical information.

We can partner with you to develop high-quality content to demonstrate your thought leadership

- ▶ Your own special focus issue or ebook on the topic of your choice
- ▶ Client case studies, interviews, and co-presentations
- ▶ Peer reviewed articles, as well as editorials and commentaries
- ▶ Video presentations and roundtables
- ▶ Podcasts
- ▶ Infographics and animations
- ▶ Webinars, both live and on demand
- ▶ Blog posting



USER DEMOGRAPHICS

Targeted sectors include:


- ▶ Biotech companies, including those at a relatively early stage of development. Our research shows that these earlier stage companies attend fewer industry conferences than those at a later stage, so *Bioconjugation Insights* offers an unparalleled opportunity to target this particular audience
- ▶ Prolific academic institutions and research hospitals, in particular those that generate spin-outs
- ▶ Pharmaceutical companies and large biotechs with a major or growing focus on bioconjugation
- ▶ Government-funded organizations (such as NIH) and NGOs
- ▶ Investors and analysts
- ▶ Solution and service providers



BIOTECH



ACADEMIC/
HOSPITAL




PHARMA/
LARGE BIOTECH



SOLUTION/
SERVICE PROVIDER,
including CROs
and CDMOs



INVESTOR/
ANALYST



GOVERNMENT/
NGO

Bioconjugation Insights has a translational focus, featuring content of value to individuals along the R&D pipeline

Data by interest area

Readership includes individuals focused on:

- ▶ Discovery and basic research
- ▶ Preclinical development and translational R&D
- ▶ Clinical research
- ▶ Product development, process development, operations, logistics and manufacture
- ▶ Diagnostics and imaging
- ▶ Regulatory affairs, QA/QC and validation
- ▶ Business development, corporate management and licensing
- ▶ Formulation and delivery platform development
- ▶ Public health and market access

Data by location



52%
NORTH AMERICA



12%
ASIA AND AUSTRALIA



33%
EUROPE



3%
REST OF WORLD

EDITORIAL CALENDAR

You are able to sponsor any of the Spotlights and/or select an issue for the content we develop together



SPOTLIGHTS

Monthly Spotlights focus BioInsights members' attention on a particular topic or technology area. We leverage an array of formats to provide a comprehensive update on the key trends, challenges and breakthroughs in a given field: independently peer reviewed Expert Insights, Opinion pieces, Interviews, Webinars, Podcasts, FastFacts videos, and more...



PODCAST SERIES

We select a key issue or challenge, then invite a range of stakeholders to proffer their opinions and share related learnings via the ever-popular, easy-to-consume podcast format.



APRIL	JUNE	JULY
Special launch issue	Evolving ADCs: expanding horizons	Targeting precision: bioconjugates in diagnostics and imaging
SEPTEMBER	OCTOBER	NOVEMBER
New frontiers: how are oligonucleotide, peptide, and other emerging conjugates extending the reach of the field?	Driving improvements in the delivery and stability of next-generation bioconjugates, including oligo, polymer, and enzyme	Overcoming challenges in the ADC manufacturing and R&D ecosystems



WHO WE WORK WITH



AGC Biologics	Phenomenex
Batavia Biosciences	Qiagen
Berkeley Lights	Repligen
Bio-Rad	Roche Custom Biotech
Bio-Techne	Sartorius
Charles River Laboratories	SCIEX
Cytiva	Single Use Support
Eppendorf	Sony Biotechnology
Eurofins	Thermo Fisher Scientific
Gyros Protein Technologies	Tosoh
Lonza	WuXi
Malvern Panalytical	
MilliporeSigma	

OPPORTUNITIES

Any of our options can be tailored to match your current marketing and business development priorities

We offer a broad range of options to help you reach your target audience, any of which can be tailored to match your current marketing and business development priorities. These include interviews, expert roundtables, podcasts, webinars, articles, video presentations, infographics, e-blasts and more.

WEBINARS


Webinars can stand alone or can be included in a Spotlight, depending on the topic and timing fit

Our 2025 webinar schedule is filling up fast

Contact n.mccall@insights.bio to discuss options and availability

Presenting a webinar with *Bioconjugation Acid Insights* gives you an efficient and cost-effective way to:

- ▶ generate qualified leads from amongst the global bioconjugation community;
- ▶ demonstrate your company's expertise and capabilities;
- ▶ stimulate discussion around a topic of significant importance to your customers;
- ▶ educate individuals on crucial regulatory, scientific or technical issues; and
- ▶ make a noise around a new product or service offering launch.



Presenting a webinar with us is an efficient and cost-effective way to generate qualified leads

Our webinar packages include:

- ▶ as much support as you need in terms of topic selection and agenda development, format selection, and speaker panel identification and invitation;
- ▶ full hosting and technical support, including planning calls with panelists and rehearsals as needed;
- ▶ a comprehensive promotional plan, including multiple email shots to our database, website and newsletter marketing, and social media;
- ▶ a moderator from our editorial team to ensure the webinar runs smoothly on the day;
- ▶ registration and attendee lists for the webinar;
- ▶ a report on the questions submitted during the live webinar so you can follow up directly with individuals afterwards and continue the discussion;
- ▶ hosting of the webinar recording on an indefinite basis with ongoing lead generation;
- ▶ webinar recording provided to you for hosting on your own site; and
- ▶ the option for us to publish an article based on the transcript of the webinar, repurposing your presentation into written format and making it search engine friendly.

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

You can view a sample of our on-demand webinars [here](#)

Here are some examples of previous webinars for our clients:



Format


Panel-style webinar with accompanying transcript-based article

Client

Bio-Techne

[VIEW THE WEBINAR HERE](#)

[READ THE ARTICLE HERE](#)



Format

Presentation-style webinar with Q&A

Client

Polyplus-transfection

[VIEW THE WEBINAR HERE](#)



Format

Live30 webinar: a 30 minute webinar focused on new technologies and their applications

Client

Mirus Bio

[VIEW THE WEBINAR HERE](#)

EXPERT ROUNDTABLES

Here are some examples of expert video roundtables for our clients:

On-demand video expert roundtables provide powerful tools for you to generate qualified leads and/or position your thought leader(s) at the heart of the debate around a topic of key importance to your company.

Our editorial team works closely with you to identify over-arching topics and discussion points, and to convene a panel of KOLs. We then liaise with the panel to define the final list of questions for discussion, record the video, and, edit the roundtable itself, and then produce a full article based on the transcript.



Format

Video (l.) and article (r.)

Client

Thermo Fisher Scientific



Format

Video plus article (l.) and poster (r.)

Client

Corning



ARTICLES

Here are some examples of articles for our clients:



INTERVIEWS AND PODCASTS

Here are some examples of interviews for our clients:

Interviews are a great way to raise awareness within the nucleic acid community, with minimal resource requirements from your team.

We can interview up to three of your scientists, executives, partners or clients, with the resulting video, podcast and/or written version included in an issue of the online journal.

Format

Video and written

Client

Merck

Format

Podcast and written

Client

Merck/Millipore Sigma




WATCH THE VIDEO AND
READ THE ARTICLE HERE



HEAR THE PODCAST AND
READ THE ARTICLE HERE

Podcasts in a variety of formats and lengths can also be produced, either in series or as one-offs

Here is an example:



Key factors to consider for successful cell therapy manufacturing: a case study
 Cell & Gene Therapy Insights 2022; 8(2): 241-249
 00:00 / 00:00
 PUBLISHED: 2 MARCH 2022
 PODCAST

View all

You can listen to the podcast here, or read the interview below.

Format

Serial podcast and written interview

Client

Thermo Fisher Scientific




CELL & GENE THERAPY INSIGHTS
 PODCAST INTERVIEW

Key factors to consider for successful cell therapy manufacturing: a case study

DAVE HUMPHRIES, Content Marketing Manager, Thermo Fisher Scientific, speaks to **Valentina Bacherucci**, QC Scientist, Children's Hospital Meyer, **Øystein Annelien**, Director of Cell Therapy, Thermo Fisher Scientific, and **Xavier de Mollerat du Jau**, Senior Director R&D Cell Therapy, Thermo Fisher Scientific.

Cell & Gene Therapy Insights 2022; 8(2): 241-249
 PUBLISHED: 2 MARCH 2022

Q DM: Today, we'll be discussing the key factors to consider for successful cell therapy manufacturing. Valentina, can you tell us a little bit more about what you do at the Meyer Children's Hospital?



CELL & GENE THERAPY INSIGHTS

Q DM: The MycoSEQ product is an interesting molecule because it can be used for a wide range of applications. As a QC scientist, what are the key factors to consider when using this product? Valentina, can you tell us a little bit more about what you do at the Meyer Children's Hospital?


VB: The most important factor for the use of MycoSEQ is the quality of the product. It's important to ensure that the product is of high quality and that it is used in a controlled environment. We also need to ensure that the product is used in a way that is consistent with the manufacturer's instructions.

QA: I understand that you have been using MycoSEQ for a while. Can you tell us a little bit more about your experience with it? Valentina, can you tell us a little bit more about what you do at the Meyer Children's Hospital?

VB: I've been using MycoSEQ for a while now and I've found it to be a very useful tool. It's easy to use and it gives you a lot of information. I've found it to be a very useful tool for QC.

DM: I understand that you have been using MycoSEQ for a while. Can you tell us a little bit more about your experience with it? Valentina, can you tell us a little bit more about what you do at the Meyer Children's Hospital?

VB: I've been using MycoSEQ for a while now and I've found it to be a very useful tool. It's easy to use and it gives you a lot of information. I've found it to be a very useful tool for QC.



HEAR THE PODCASTS AND READ THE ARTICLE HERE

Listen to the full podcast:

Podcasts Publishing
 Key factors to consider for successful cell therapy manufacturing: a case study
 Share

Listen to each individual question and answer:

Podcasts Publishing
 Can you tell us a little bit more about what you do at the Meyer Children's Hospital?
 Share

Podcasts Publishing
 What are the QC or analytical tests in your process to ensure the safety and quality of p...
 Share

Podcasts Publishing
 What are the challenges you have identified and what are we working on at Thermo Fis...
 Share

Podcasts Publishing
 Can you detail your experience with Maria Scarfone implementing the MycoSEQ analyt...
 Share

Podcasts Publishing
 Are there any other factors that you think will be critical in the future?
 Share

Podcasts Publishing
 Are there any other thoughts that we haven't touched upon?
 Share

VIDEO PRESENTATIONS

Our FastFacts work well for educational and lead generation purposes

Here are some examples of Fast Facts videos for our clients:

Our FastFacts videos are 10–15 minute edited presentations, accompanied by a poster summarising the key learning points. They are designed for the presentation of app notes, validation data, case studies, scientific posters, or product demonstrations.

FASTFACTS

TESSA technology: a new paradigm in AAV manufacturing

Cell & Gene Therapy Insights 2020, 430, 1225
10.1009/cgti.2020.124
PUBLISHED 1 OCTOBER 2020

FASTFACTS


Ryan Cawood

Watch the video or read the poster to learn:

- Benefits and drawbacks of current AAV viral vector production methods
- How TESSA (Enabling Self-Sustaining Adenovirus) TESSA allows efficient, scalable AAV manufacture
- Results from studies comparing TESSA with conventional methods

About the speaker
Ryan Cawood, National Cancer Institute (NCI), after working for 4 years designed and implemented the company was to simplify and standardize the process of DNA engineering called "Fast Fact" (the development of the "Fast Fact" platform through in-house research and his background in genetic engineering and strategy to grow and grow the business. Ryan is currently working on the development of the "Fast Fact" platform through in-house research and his background in genetic engineering and strategy to grow and grow the business. Ryan is currently working on the development of the "Fast Fact" platform through in-house research and his background in genetic engineering and strategy to grow and grow the business.

Client
OXGENE



FASTFACTS

GMP compliant residual PEIpro® test: one step closer to commercialization

Cell & Gene Therapy Insights 2020, 430, 1445
10.1009/cgti.2020.128
PUBLISHED 1 NOVEMBER 2020


FASTFACTS

Watch the video or read the poster to learn:

- Why perform residual PEI testing?
- How are critical raw materials quantified and detected?
- How does the Residual PEIpro test guarantee specific detection and accurate quantification of PEI?

About the speaker
Maha Reddy is a Senior Scientist in Chemistry at Polyplus-transfection. With a PhD from the University of Birmingham and post-doctoral experience at Harvard NeuroDiscovery Center, she is currently working on the development of innovative targeted delivery vehicles.

Client
Polyplus-transfection



FASTFACTS

Simplifying AAV protein analytics with Maurice

Cell & Gene Therapy Insights 2021, 702, 207
10.1009/cgti.2021.059
PUBLISHED 20 APRIL 2021

FASTFACTS


Chris Heeger PhD

Watch the video or read the poster to learn how to achieve faster, better analysis integrated Maurice CE SDS PLUS system, including:

- CE SDS analysis of AAV protein purity
- IEF analysis of AAV charge heterogeneity

About the speaker
Dr Chris Heeger, Director of Applications Science for the Analytical Solutions Division, Pharming from Cancer Institute in Berkeley Development, Purification and Scale-Up, 2011, starting as a Field Applications Scientist, and subsequently further building the team. Chris is currently working on the development of the Maurice CE SDS PLUS system, including: CE SDS analysis of AAV protein purity, IEF analysis of AAV charge heterogeneity.

Client
Protein Simple



FASTFACTS

Identify and select optimal T cell phenotypes

Cell & Gene Therapy Insights 2021, 710, 81
10.1009/cgti.2021.046
PUBLISHED 22 FEBRUARY 2021

FASTFACTS


James Lougren

Watch the video or read the poster to learn:

- What are the key challenges facing adoptive cell therapy development?
- How can we identify the best T cells for adoptive therapy?
- How can multidimensional, functional assays on single T cells help develop powerful and effective cell therapy products?

About the speaker
James Lougren is an accomplished science executive with a distinguished track record in the industry leading global product portfolio. He currently serves as the VP of Research and Development and is responsible for the company's research and product development. He is currently working on the development of innovative targeted delivery vehicles.

Client
Berkeley Lights



INFOGRAPHICS

Here are some examples of infographics that we have produced for our clients:

Our team are experts in communicating complex scientific information via visual formats, including infographics (static, voiced, and animated), PPT presentations and illustrations.



They work closely with your team to define contents and style, and the resulting content can be published in *Bioconjugation Insights* or simply provided to you for your own use.

Format

Interactive, voiced infographic

Client

Thermo Fisher Scientific



Format




Interactive, voiced infographic



Client

Thermo Fisher Scientific

SCIENTIFIC ILLUSTRATIONS

We work from your sketch or concept to create schematics or illustrations of your products or services





e-BLASTS

Our 2025 schedule is open for bookings

Contact n.mccall@insights.bio to discuss options and availability

We offer a strictly limited number of third-party e-blasts to our registered users.

PREMIUM SERVICES

mRNA manufacturing and analytics

With the recent surge in use of mRNA as a vaccine and therapeutic modality, optimizing and understanding the mechanisms and manufacturing of mRNA for biopharmaceuticals has never been of greater importance.

Current value of the global mRNA vaccine market is projected to reach over \$50 billion by 2026

COVID-19 has a massive impact on the mRNA vaccine

US\$ 53 billion

Use this infographic to guide you through the upstream and downstream steps in mRNA manufacture, along with the associated analytics

DNA TEMPLATE PREPARATION

Template design & plasmid production

- TARGET GENE DISCOVERY**
Target genes are discovered using techniques such as next-generation sequencing.
- PLASMID CREATION**
Once a gene of interest has been identified, the target sequence can be integrated into a plasmid.
- GENE AMPLIFICATION**
Plasmid DNA (gDNA) is amplified in host bacteria, typically E. coli, which grows to a single-use fermenter.

ANALYTICS

For technologies used to identify critical quality attributes and impurities are fitted below:

- Agarose gel electrophoresis**
To confirm expected size of amplicons
- qPCR**
Quantify amount of gDNA
- Sequencing**
Confirming sequence
- UV absorbance**
DNA quantification
- Process-related impurity identification**
Identify residual host cell proteins, CHO and HSA
- SP-ITC**
Residual host protein and HSA detection

PLASMID PURIFICATION

PURIFICATION
To achieve a high level of supercoiled plasmid

LIMARIZATION
With restriction enzymes that cleave DNA at specific sequences

PURIFICATION
Recovery of the linearized plasmid

mRNA SYNTHESIS

mRNA in vitro transcription and capping

mRNA is synthesized through the process of in vitro transcription (IVT) using linearized gDNA template

RESIDUAL DNA TESTING: Homebrew vs off-the-shelf solutions

STEPS TO SETTING UP YOUR OWN RESIDUAL DNA TESTING SOLUTION

- DEFINE A CLEAR BENCHMARK FOR THE TARGETING OF RESIDUAL BIOLOGIC MOLECULE RELEASE
- IDENTIFY THE ANALYTICAL METHODS AND ASSAYS TO BE USED
- DEVELOP A STANDARDIZED WORKFLOW
- VALIDATE THE METHOD
- IMPLEMENT THE METHOD
- MONITOR THE METHOD
- REVIEW THE METHOD
- UPDATE THE METHOD
- REPORT THE RESULTS
- ARCHIVE THE DATA
- DISSEMINATE THE INFORMATION
- CONTINUE TO IMPROVE THE METHOD

DOWNSTREAM

mRNA purification
mRNA is produced in a cell-free system animal derived sera. This simplifies downstreams

However, the reaction mixture contains including enzymes, residual NTPs and other unwanted components such as truncated mRNA, DNA templates, components and NTPs

ULTRAFILTRATION & BUFFER EXCHANGE
Reduce volume and remove unwanted components

AFFINITY CHROMATOGRAPHY
Process related components such as truncated mRNA, DNA templates, components and NTPs

ION EXCHANGE CHROMATOGRAPHY
Reduce mRNA and encapsulated DNA products from the final product

ULTRAFILTRATION IN BUFFER EXCHANGE
Reduce volume and final 0.2 µm filtration

PURIFIED mRNA

Formulation, fill and finish

The purified mRNA is encapsulated in a drug delivery vehicle, such as a lipid nanoparticle (LNP) or another lipid or carrier molecule

We offer a number of premium options, both for content creation and for market research. These include:

- ▶ bringing together KOL panels to discuss the topics of your choice, publishing the output as an ebook, video, and written roundtable, or other suitable content format;
- ▶ designing infographics, which can be animated and/or voiced, ideal for communicating complex technical or scientific information in an easily digestible format;
- ▶ inviting industry or academic subject matter experts to join your live webinars to add their opinions to the discussion;
- ▶ building and deploying surveys amongst our users, providing detailed reports on the responses; and
- ▶ bringing together focus groups to discuss your products/services, or topics of interest to you.

Plasmid DNA Manufacturing and Analytics

The rapid increase of the gene therapy pipeline and genetic vaccination for various infectious diseases require large-scale production of high-quality plasmid DNA (pDNA) in gene therapy applications. pDNA is a starting material for cell transfection, therefore, producing sufficient quantities of it is essential to scale up. Therefore, manufacturing and analytics processes to produce large quantities of pDNA.

Global plasmid DNA manufacturing market value 2022
\$400-700 million

APPLICATIONS OF pDNA

pDNA is used as a starting material in the manufacture of many advanced therapies. It can also be used as a therapeutic itself in DNA vaccines.

- DNA vaccines & therapies against protein therapies
- Template for mRNA manufacture
- Viral vector manufacturing
- Gene modified cell expression (i.e., CAR-T cells)

CHALLENGES IN THE SUPPLY OF pDNA

- Complex supply chain
- Production and capacity bottlenecks caused by high demand
- Costs of reagents
- Involving regulatory landscape
- Quality assurance

pDNA and contaminants are of similar size and charge
 Large size of product
 High negative charge
 pDNA is sensitive to shear stress and nuclease degradation
 Intermediate process pools can be highly viscous
 High volume of impurities in the starting material (~1% pDNA)
 Conventional chromatography resins exhibit low binding capacities for pDNA
 High purity is required

MANUFACTURING CHALLENGES

pDNA MANUFACTURE

PLASMID SYNTHESIS

- Gene creation
- Gene insertion into cloning vector

UPSTREAM

During the upstream process, pDNA is produced in host cells. pDNA is typically used as the template to synthesize plasmid. Different process produce large quantities as they proliferate rapidly and synthesize

Seed expansion & production

- Introduction of the seed strain
- Fermentation expansion of the cells, and maintain pDNA

DOWNSTREAM

During the downstream process, pDNA is extracted from the host cells and purified from the host cell proteins, DNA and other impurities in the fluids

Cell harvest

Cells are concentrated and the fermentation broth is removed.

- Separation of cells can be achieved using flow filtration.
- Separation of cells can be achieved using flow filtration.

Extraction of plasmid from high cell density

Shear damage due to centrifugation can reduce the yield

ANALYTICS

pDNA is subject to requirements for purity, efficiency and yields.

There are three recognized plasmid quality grades dependent on the use in this therapeutic, namely: the manufacture of CAR-grade plasmid.

ANALYTICS TESTING

Residual host cell proteins

- ELISA
- PCR

Host cell E. coli protein

- gPCR

Host E. coli RNA:



- Agarose and electrophoresis (AGE)
- RT-qPCR

[illegible]

OUR OTHER PUBLICATIONS

In addition to *Bioconjugation Insights*, BioInsights also publishes *Cell & Gene Therapy Insights*, *Vaccine Insights*, and *Nucleic Acid Insights*

If you would like to distribute content to more than one of the cell and gene therapy, nucleic acid, and vaccine communities, we can promote it across multiple journals and market it to more than one set of users



CELL & GENE THERAPY INSIGHTS

Launched in 2014, *Cell & Gene Therapy Insights* is our inaugural online, open access, peer-reviewed journal with a translational focus.

Cell & Gene Therapy Insights addresses the important challenges and advances in the field of cell and gene therapy, publishing original research, reviews, commentary articles, clinical trial reports, and much more.

VACCINE INSIGHTS

Launched in 2022, *Vaccine Insights* is a peer-reviewed, open-access journal providing insights into development and manufacture of prophylactic and therapeutic vaccines. The journal brings together leading experts from pharma, biotech, academia and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine development and manufacture across all disease areas.

NUCLEIC ACID INSIGHTS

Launched in 2022, *Vaccine Insights* is a peer-reviewed, open-access journal providing insights into development and manufacture of prophylactic and therapeutic vaccines. The journal brings together leading experts from pharma, biotech, academia and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine development and manufacture across all disease areas.